Aromasin (exemestane) is a steroidal, irreversible inhibitor, whereas agents such as anastrozole and letrozole are non-steroidal, reversible inhibitors. This distinction can affect side-effect profiles and drug-interaction potential.
Exemestane is occasionally prescribed off-label to suppress estrogen in men with conditions like gynecomastia, but it is not approved for this purpose in the UK. Such use should only occur under specialist supervision.
Significant reductions in bone mineral density may be detectable after 6-12 months of continuous estrogen suppression, which is why baseline and periodic DXA scans are recommended.
Aromasin can modestly raise LDL cholesterol. Patients following a cholesterol-lowering diet should have their lipid profile monitored, but the medication is not contraindicated.
Official UK tablets are round, white, and bear the imprint “25 EXE” on one side. Always verify against the pharmacy-issued packaging.
Yes, provided you carry the prescription label, a copy of the prescribing clinician’s note, and keep the medication in its original packaging. Some countries require a paper prescription at customs.
Exemestane may slightly alter coagulation parameters, potentially affecting INR or other clotting assays. If regular blood-testing is required for employment or athletics, inform the testing authority of your medication.
Even in warm environments, keep the tablets in a cool, dry place away from direct sunlight. If the ambient temperature exceeds 30 °C for prolonged periods, use a temperature-controlled container or store the medication in a refrigerator (do not freeze).
St John’s wort is a potent CYP3A4 inducer and may lower exemestane levels, reducing efficacy. Patients should discuss all herbal and over-the-counter products with their prescriber.
Report the symptom to your oncology team promptly. They may adjust the dose, add analgesics, or consider a temporary drug holiday, depending on overall treatment goals.
Aromasin is the brand name for exemestane, an oral aromatase inhibitor used primarily in the treatment of hormone-responsive breast cancer. In the United Kingdom, exemexstane is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as a 25 mg pill.
Exemestane belongs to the class of steroidal aromatase inhibitors. Aromatase is an enzyme that converts androgens (such as testosterone) into estrogens. By binding irreversibly to the aromatase enzyme, exemestane reduces the production of estrogen throughout the body.
Lowering estrogen deprives estrogen-receptor-positive breast cancer cells of a growth signal, slowing tumor progression.
In the UK, exemestane is approved for:
These indications are based on clinical trials demonstrating improved disease-free survival compared with placebo or alternative hormonal agents.
Exemestane is sometimes prescribed off-label for:
These uses are not approved by the MHRA and should only be considered under specialist supervision.
These effects are generally manageable with lifestyle adjustments or supportive medications.
This article provides educational information about Aromasin (exemestane) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
